PM
SYRE icon

Prosight Management’s Spyre Therapeutics SYRE Stock Holding History

Prosight Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,921
Closed -$1.21M – 47
2025
Q1 		$1.21M Sell
74,921
-5,079
-6% -$106K 0.4% 33
2024
Q4 		$1.86M Buy
+80,000
New +$2.35M 0.51% 30
2024
Q1 		– Sell
-55,000
Closed -$1.18M – 51
2023
Q4 		$1.18M Buy
+55,000
New +$758K 0.48% 30

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Prosight Management's SYRE Position: Q2 2025 in Review

Prosight Management sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 74,921 shares — an estimated $1.21M sold.

Prosight Management first reported a position in SYRE in Q4 2023 and held it in 3 quarters. The position peaked at $1.86M in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • Prosight Management reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Prosight Management sold 74,921 Spyre Therapeutics shares in Q2 2025, an estimated $1.21M.
  • Prosight Management first reported a position in Spyre Therapeutics in Q4 2023 and held it in 3 quarters.
  • Prosight Management's Spyre Therapeutics position peaked at $1.86M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on Prosight Management's 13F filing for Q2 2025, filed 14 Aug 2025.